Should glycated haemoglobin (HbA1c) be used to detect people with type 2 diabetes mellitus and impaired glucose regulation?

Postgraduate Medical Journal

Volumn 86, Issue 1021, 2010, Pages 656-662

  Mostafa, Samiul A ^a   Davies, Melanie J ^a   Srinivasan, Balasubramanian Thiagarajan ^a   Carey, Marian E ^b   Webb, David ^a   Khunti, Kamlesh ^c  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

DIAGNOSTIC VALUE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INTERMETHOD COMPARISON; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; REVIEW; SCREENING TEST;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FORECASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS;

EID: 78149359737     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.091215     Document Type: Review

References (58)

1. Eastman RC, Cowie CC, Harris MI. Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk. Diabetes Care 1997;20:127-8.
2. QOF. Quality and Outcomes Framework data from all four countries for the year 2004/5.
3. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998;21:296-309.
4. IDF Diabetes Atlas - Prevalence estimates of diabetes mellitus. 2005. http:// www.eatlas.idf.org (accessed 21 Jul 2005).
5. King H, Aubert RE, Herman WH. Global burden of Diabetes, 1995-2025: prevalence numerical estimates, and projections. Diabetes Care 1998;21:414-31.
6. World Health Organisation. Report of a World Health Organisation and International Diabetes Federation Meeting: Screening for Type 2 Diabetes. Geneva: World Health Org, 2003.
7. Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-19.
8. Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008;336:1180-5.
9. DECODE study group, European Diabetes Epidemiology Group. Glucose Tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617-21.
10. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
11. Davies MJ, Raymond NT, Day JL, et al. Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med 2000;17:433-40.
12. Saad MF, Knowler WC, Pettitt DJ, et al. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 1998;319:1500-6.
13. Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycemia. Diabetologia 2003;46:M2-8. (Pubitemid 36543097)
14. Ko GT, Chan JC, Woo J, et al. Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population. Diabetes Care 1998;21:2094-7.
15. Gimeno SG, Ferreira SR, Franco LJ, et al. Comparison of glucose tolerance categories according to World Health Organization and American Diabetes Association diagnostic criteria in a population-based study in Brazil. The JapaneseeBrazilian Diabetes Study Group. Diabetes Care 1998;21:1889-92.
16. Ko GTC. Screening and diagnosis of diabetes in Asians. Hong Kong Med J 2000;6:53-9.
17. Perry RC, Shankar RR, Fineberg N, et al. Early Diabetes Intervention Program (EDIP). HbA1c measurement improves the detection of type 2 diabetes in high risk individuals with non diagnostic levels of a fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care 2001;24:465-71.
18. Tanaka Y, Atsumi Y, Asahina T, et al. Usefulness of revised fasting plasma glucose criterion and characteristics of the insulin response to an oral glucose load in newly diagnosed Japanese diabetic subjects. Diabetes Care 1998;21:1133-7.
19. Barr RG, Nathan DM, Meigs JB, et al. Tests of glycaemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med 2002;137:263-72.
20. Jeffcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 2004;21:657-65.
21. Tahara Y, Shima K. The response of GHB to stepwise plasma glucose change over time in diabetic patients. Diabetes Care 1993;16:1313-14. (Pubitemid 23259881)
22. Goldstein DE, Little RR, Wiedmeyer HM, et al. Glycohaemoglobin testing in diabetes mellitus: assay methods and clinical interpretation. In: Vasselii JR, Maggio CA, Scriabine A, eds. Drug in Development. Vol 1. Branford, CT: Neva Press, 1993: 253-67.
23. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Report of a WHO/IDF Consultation, WHO Document Production Services, Geneva, Switzerland, 2006. http://www.who.int/diabetes/publications/ Definition%20and%20diagnosis%20of%20diabetes-new.pdf.
24. Ealovega MW, Tabaei BP, Brandle M, et al. Opportunistic screening for diabetes in routine clinical practice. Diabetes Care 2004;27:9-12.
25. Kim KS, Kim SK, Lee YK, et al. Diagnostic value of glycated haemoglobin HbA(1c) for the early detection of diabetes in high-risk subjects. Diabet Med 2008;25:997-1000.
26. Droumaguet C, Balkau B, Simon D, et al; DESIR Study Group. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2006;29:1619-25.
27. Manley SE, Sikaris KA, Lu ZX, et al. Validation of an algorithm combining haemoglobin A(1c) and fasting plasma glucose for diagnosis of diabetes mellitus in UK and Australian populations. Diabet Med 2009;26:115-21.
28. Buell C, Kermah D, Davidson MD. Utility of A1c for diabetes screening in the 1999-2004 NHANES population. Diabetes Care 2007;30:2233-5.
29. Rohlfing CL, Little RR, Wiedmeyer MH, et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the US population. Diabetes Care 2000;23:187-91.
30. International Expert Committee. International Expert Committee Report on the role of the A1c Assay in the Diagnosis of Diabetes. Diabetes Care 2009;32: 1327-34.
31. Anon. American Diabetes Association Position statement: Standards of Medical Care in Diabetes-2010. Diabetes Care 2010;33(Supp1 1):S11-61.
32. American Diabetes Association; European Association for the Study of Diabetes; International Federation of Clinical Chemistry and Laboratory Medicine; International Diabetes Federation. Consensus statement on the worldwide standardisation of the HbA1c measurement. Diabetologia 2007;50:2042-3.
33. Nathan DM, Kuenen J, Borg R, et al. RJ for the A1c Derived Average Glucose (ADAG) Study Group. Translating the A1c assay into estimated average glucose values. Diabetes Care 2008;31:1473-8.
34. Rohlfing C, Wiedneger HM, Little R, et al. Biological variation of glycated haemoglobin Clin Chem 2002;48:1116-18.
35. Petersen PH, Jorgensen LG, Brandslund I, et al. Consequences of bias and imprecision in measurements of glucose and HbA1c for the diagnosis and prognosis of diabetes mellitus. Scand J Clin Lab Invest Suppl 2005;240:51-60.
36. Ollerton RL, Playle R, Ahmed K, et al. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 1999;22:394-8.
37. Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-72.
38. Khaw KT, Wareham N, Bingham S, et al. Association of Hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cnacer in Norfolk. Ann Intern Med 2004;141:413-20.
39. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001;322:15-18.
40. Myint PK, Sinha S, Wareham NJ, et al. Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study: a threshold relationship? Stroke 2007;38:271-5.
41. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.
42. Mostafa SA, Davies MJ, Webb D, et al. The potential impact of using glycated haemoglobin, HbA1c, as the preferred diagnostic tool for Type 2 Diabetes Mellitus. Diabetic Medicine 2010. Diabet Med 2010;72:762-9.
43. Carson AP, Reynolds K, Fonseca VA, et al. Comparison of A1c and fasting glucose criteria to diagnose diabetes amongst US adults. Diabetes Care 2010;33:95-7.
44. Davidson MB, Schriger DL, Peters AL, et al. Relationship Between Fasting Plasma Glucose and Glycosylated Hemoglobin: Potential for False-Positive Diagnoses of Type 2 Diabetes Using New Diagnostic Criteria. JAMA 1999;281:1203-10.
45. Zhou XH, Ji LN, Luo YY, et al. Performance of HbA1c for detecting newly diagnosed diabetes and pre-diabetes in Chinese communities living in Beijing. Diabet Med 2009;26:1262-8.
46. Van 't Riet E, Marjan Alssema M, Rijkelijkhuizen JM, et al. Relationship Between A1C and Glucose Levels in the General Dutch Population. The New Hoorn Study. Diabetes Care 2010;33:61-6.
47. Mohan V, Vijayachandrika V, Gokulakrishnan K, et al. HbA1c cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care 2010;33:515-9.
48. Inoue K, Matsumoto M, Kobayashi Y. The combination of fasting glucose and glycosylated haemoglobin pedicts Type 2 diabetes in Japanese workers. Diabetes Res Clin Pract 2007;77:451-8.
49. NGSP website. Harmonizing haemoglobin A1c testing, http://www.ngsp.org/ factors.asp (accessed 28 May 2010).
50. Saudek CD, Derr RL, Kalyani RR. Assessing glycaemia in diabetes using self-monitoring blood glucose and haemoglobin A1c. JAMA 2006;295:1688-97.
51. Pani LN, Korenda L, Meigs JB, et al. Effects of aging on A1C levels in individuals without diabetes. Diabetes Care 2008;31:1991-6.
52. Herman WH, Ma Y, Uwaifo G, et al. Racial and ethnic differences in haemoglobin A1c among patients with impaired glucose tolerance in Diabetes Prevention Programme. Diabetes Care 2007;30:2756-8.
53. Manley S, Nightingale P, Stratton I, et al. Diagnosis of diabetes: HbA1c versus WHO criteria. Diabetes and Primary Care 2010;12.
54. Mitka M. Hemoglobin A1c poised to become preferred test for diagnosing diabetes. JAMA 2009;301:1528.
55. Putting Prevention First, NHS Health check: Vascular Risk Assessment and Management. Department of Health. Publication 29452. Released April 2009.
56. Christensen DL, Witte DR, Kaduka L, et al. Moving to an HbA1c based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care 2010;33:580-2.
57. Mostafa SA, Davies MJ, Webb D, et al. The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. Diabetes Res Clin Pract 2010;90:100-8.
58. Lu ZX, Walker KZ, O'Dea K, et al. A1C for screening and diagnosis of type 2 diabetes in routine clinical practice. Diabetes Care 2010;33:817-19.